Org 48762-0

Org 48762-0 (UR13870) is a potent, orally active and selective p38 inhibitor with an EC50 of 0.1 μM for p38α kinase. Org 48762-0 shows a high degree of kinase selectivity for p38α and p38β over other kinases. Org 48762-0 reduces Lipopolysaccharides (HY-D1056) (LPS) -induced TNFα release. Org 48762-0 can be used for the study of rheumatoid arthritis (RA) and Werner syndrome[1][2].

Product Specifications

CAS Number

[755753-89-0]

Product Name Alternative

UR13870

UNSPSC

12352005

Target

P38 MAPK

Type

Reference compound

Related Pathways

MAPK/ERK Pathway

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/org-48762-0.html

Purity

99.99

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CN1N=C2C(C(C3=CC=C(F)C=C3)=C(C4=CC=NC=C4)C(C5=CC=C(F)C=C5)=N2)=C1

Molecular Formula

C24H16F2N4

Molecular Weight

398.41

References & Citations

[1]K Mihara, et al. A potent and selective p38 inhibitor protects against bone damage in murine collagen-induced arthritis: a comparison with neutralization of mouse TNFalpha. Br J Pharmacol. 2008 May;154 (1) :153-64. |[2]Bagley MC, et al. Synthesis of the highly selective p38 MAPK inhibitor UR-13756 for possible therapeutic use in Werner syndrome. Future Med Chem. 2010 Feb;2 (2) :193-201.